109P - Sequential administration of EGFR-TKI and pemetrexed achieved a long period of response in advanced NSCLC patients with EGFR-mutant tumors

Date 07 May 2017
Event ELCC 2017
Session Poster Display Session
Topics Thoracic malignancies
Non-small-cell lung cancer
Presenter Yue-Yun Chen
Citation Annals of Oncology (2017) 28 (suppl_2): ii28-ii51. 10.1093/annonc/mdx091
Authors Y. Chen1, Q. Zhu2, L. Dai2, Z. Ding2
  • 1Division Of Thoracic Cancer, Cancer Center, West China Hospital, Huaxi, Sichuan University, 610041 - Chengdu/CN
  • 2Division Of Thoracic Cancer, Cancer Center, West China Hospital, Huaxi, Sichuan University, Chengdu/CN

Abstract

Background

The study aimed to explore the efficacy of sequential administration of EGFR TKI and pemetrexed doublet chemotherapy (P), two effective therapies, in advanced NSCLC patients with EGFR mutant tumors.

Methods

This was a retrospective study where patients prescribed with EGFR-TKI (gefitinib or icotinib) from Jan 2013 to Jan 2016 were screened. Patients must have metastastic diseases harboring TKI-sensitizing EGFR mutation. They must be older than 18 years, and have evaluable target lesions. Whether TKI or P was used in the first line, it must be switched to the other in the second line. PFS in both first line (PFS1) and second line (PFS2) was collected.

Results

We screened totally 550 patients (gefitinib n = 455, icotinib n = 95) to enroll a cohort of 37 patients. However, 1 patient was found to subject adjuvant TKI therapy and therefore was excluded. They were all adenocarcinoma except 1 adenosquamous carcinoma. Gender, good PS, mutation type were equally distributed (male n = 19 vs female n = 17, PS:0 n = 21 vs PS:1 n = 15, exon 19 del n = 14 vs L858R n = 14 vs other type n = 8). The median age was 50.5 years. For the whole cohort, the total PFS (PFS1+PFS2) was 18.1 m (95%CI: 15.2-21.1 m). For the patients receiving first-line TKI, PFS1 and PFS2 were 10.3 m and 6.6 m. And for those receiving first-line P, PFS1 and PFS2 were 3.4 m and 11.5 m.

Conclusions

Our results argued the sequential usage of TKI and P achieve a long period of response in advanced NSCLC patients with EGFR-mutant tumors, comparable to that of synchronous administration (15.4 m, JMIT study).

Clinical trial identification

NA

Legal entity responsible for the study

West China Hospital, Sichuan University

Funding

West China Hospital, Sichuan University

Disclosure

All authors have declared no conflicts of interest.